TOP HEADLINES

Featured Story

  • Roche's M&A party rages on with Kapa Biosystems deal

    Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.

Veritas Genetics gets CE mark to conduct BRCA testing in Europe

Boston's Veritas Genetics received a CE mark to conduct BRCA gene testing for likelihood of inheriting breast and inheriting cancer in Europe.

 

Roche shops around for sequencing tech with Lumora buy

Roche has been hot on the trail of sequencing deals this past year, snatching up companies to build out its genomic analysis offerings. In its latest move, the company is buying sequencing products from molecular diagnostics firm Lumora to support its burgeoning portfolio.

LabCorp announces nationwide launch of its VistaSeq multigene cancer panel

LabCorp announced that its 27-gene VistaSeq Hereditary Cancer Panel to detect patients with increased risk of various cancers--including breast, ovarian, melanoma, pancreatic colorectal, endometrial, gastric and prostate cancer--is now available nationwide.  

Sequenom strikes liquid biopsy research deal with UC San Diego Moores

Sequenom has already made waves with its noninvasive prenatal diagnostic, revealing earlier this year that its technology could uncover signs of cancer in pregnant women. Now, the company is moving forward with its new liquid biopsy test, teaming up with the UC San Diego Moores Cancer Center to use its tool to monitor cancer patients and match them with a suitable therapy. 

Invitae gears up for next chapter with genome management aspirations

Invitae has grown by leaps and bounds since entering the market in 2013, after a U.S. Supreme Court ruling found that patents for human DNA were invalid. With testing volumes on the rise and revenues growing steadily, the company is set to enter its second phase of business, CEO Randy Scott told FierceDiagnostics.

MORE NEWS

From Our Sister Sites

FierceBiotech

Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.

FierceMedicalDevices

Engineer Scott Leibrand and diabetes patient Dana Lewis have created an artificial pancreas, via years of constant experimentation and iterative upgrades.